Conference Correspondent

Conference Correspondent

The combination of ibrutinib and CTL119, an anti-CD19 CAR T-cell antibody, showed promising results in a pilot trial with ibrutinib, with a high rate of patients achieving minimal residual disease–negative status.
After 7 years of follow-up, sustained progression-free survival and overall survival rates were seen with ibrutinib, as well as stable or improved complete response rates over time.
In a phase 2 trial, the combination of ibrutinib and venetoclax was effective in patients with previously untreated, high-risk chronic lymphocytic leukemia (CLL), with no unforeseen safety signals.
The combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of undetectable minimal residual disease in previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL).
The ALLIANCE study showed that ibrutinib produces superior progression-free survival to standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL).
The combination of ibrutinib with obinutuzumab represents an effective chemotherapy-free treatment option for first-line chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), including patients with high-risk genetic abnormalities.
The Bruton’s tyrosine kinase inhibitor acalabrutinib shows promise as a tolerable, effective monotherapy option for patients with previously untreated chronic lymphocytic leukemia.
In evaluating the combination regimen of obinutuzumab, ibrutinib, and venetoclax as a potential limited-duration option in chronic lymphocytic leukemia (CLL), researchers reported a high mid-therapy response rate of relapsed/refractory patients with promising rates of minimal residual disease–negativity.
Researchers evaluated venetoclax plus rituximab versus bendamustine plus rituximab in inducing deep, durable responses in patients with chronic lymphocytic leukemia, as measured by the rate of minimal residual disease.
Pooled safety data of eravacycline in 3 comparator-controlled studies for the treatment of complicated intra-abdominal infections showed that it was generally well-tolerated compared with ertapenem and meropenem.
Page 2 of 19
Results 11 - 20 of 190
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME